SCHEDULE: Deep Track Capital Amends Abivax Stake
Beneficial Ownership Report
Deep Track Capital, LP and affiliated entities have updated their beneficial ownership in Abivax SA to 4.78% of outstanding Ordinary Shares.
Summary
- Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 3,480,144 Ordinary Shares of Abivax SA.
- This represents 4.78% of Abivax SA's outstanding Ordinary Shares.
- The ownership is held with shared voting power and shared dispositive power.
- The beneficial ownership calculation is based on 72,784,660 Ordinary Shares outstanding as of June 30, 2025.
- This document is an Amendment No. 2 to a Schedule 13G filing.
Sentiment
Score: 5
Explanation: Neutral. This is a routine disclosure of beneficial ownership, not indicative of positive or negative company performance or strategic shifts.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement; also the date for outstanding shares calculation. |
| 07/17/2025 | Date Abivax SA filed outstanding shares information with Euronext. |
| 08/14/2025 | Date of filing and signature date for the Schedule 13G Amendment. |
Keywords
Abivax SA, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depository Shares, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.